The U.S. Supreme Court reached a decision Monday in the case of the Federal Trade Commission vs. Actavis.
The court found that pay-for-delay settlements of drug patient litigation—settlements in which brand name drug manufacturers pay their generic competitors to delay the availability of cheaper generic drugs—may be challenged as potential violations of the antitrust law...